...
首页> 外文期刊>Archives of pathology & laboratory medicine >Human papillomavirus typing and viral gene expression analysis for the triage of women with abnormal results from papanicolaou test smears to colposcopy.
【24h】

Human papillomavirus typing and viral gene expression analysis for the triage of women with abnormal results from papanicolaou test smears to colposcopy.

机译:人乳头瘤病毒分型和病毒基因表达分析,用于从乳头状涂片检查到阴道镜检查结果异常的妇女分流。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: A cascade of molecular tests for human papillomavirus (HPV), as a follow-up to Papanicolaou test screening, could eliminate unnecessary colposcopy. Tests based on detection of HPV E6 messenger RNA (mRNA) are already being used as screening tools, but there is a good biological rationale for expecting that an increase in the relative amounts of HPV E6 mRNA in cervical samples may better predict cancerous transformation. OBJECTIVE: To compare some of the available diagnostic methods and our novel method of relative quantification (RQ) of HPV gene expression for the effective triage of women with abnormal results from Papanicolaou tests to colposcopy. DESIGN: Sensitivities, specificities, and likelihood ratios were calculated for repeat Papanicolaou test smears, HPV DNA polymerase chain reactions, HPV genotyping, HPV-16 E6 mRNA detection, and the RQ of HPV-16 E6 mRNA calibrated to cellular RNA and DNA levels and standardized to viral load. RESULTS: Human papillomavirus genotype in combination with a repeat Papanicolaou test can be used to categorize most women (96%) with cervical intraepithelial neoplasia of grade 2 or higher for colposcopy while eliminating 44% of women with cervical intraepithelial neoplasia 1 or less. The presence of HPV-16 E6 mRNA (P < .001) and RQ of HPV-16 E6 mRNA (P < .001) displayed significant median differences among the various grades of cervical intraepithelial neoplasia. Further testing of women who are positive for HPV-16 demonstrated that the RQ of E6 mRNA has diagnostic potential when combined with Papanicolaou testing in populations with higher disease prevalence. CONCLUSIONS: The RQ of HPV E6 mRNA and HPV genotype could be useful in a cascade of diagnostic testing designed to refer women with findings of cervical abnormalities for colposcopy or treatment while reducing triage numbers.
机译:背景:对人类乳头瘤病毒(HPV)进行一系列分子检测,作为对Papanicolaou检测筛选的后续措施,可以消除不必要的阴道镜检查。基于检测HPV E6信使RNA(mRNA)的测试已被用作筛选工具,但是有很好的生物学原理可以预期宫颈样品中HPV E6 mRNA相对含量的增加可以更好地预测癌变。目的:比较一些可用的诊断方法和我们新的HPV基因表达相对定量(RQ)相对诊断方法,用于有效分流从Papanicolaou测试到阴道镜检查结果异常的女性。设计:针对重复的帕潘尼古拉测试涂片,HPV DNA聚合酶链反应,HPV基因分型,HPV-16 E6 mRNA检测以及根据细胞RNA和DNA水平校正的HPV-16 E6 mRNA的RQ,计算出敏感性,特异性和似然比。标准化以适应病毒载量。结果:人类乳头瘤病毒基因型与重复的Papanicolaou测试相结合,可用于对大多数2级或更高级别宫颈上皮内瘤样病变的妇女(96%)进行阴道镜检查,同时消除44%的1岁以下宫颈上皮内瘤变的妇女。 HPV-16 E6 mRNA的存在(P <.001)和HPV-16 E6 mRNA的RQ(P <.001)在各个级别的宫颈上皮内瘤变之间显示出显着的中值差异。对HPV-16阳性妇女的进一步检测表明,与帕潘尼古拉试验相结合,在疾病患病率较高的人群中,E6 mRNA的RQ具有诊断潜力。结论:HPV E6 mRNA的RQ和HPV基因型可能在一系列诊断测试中有用,这些诊断测试旨在将发现宫颈异常的妇女转诊至阴道镜或治疗,同时减少分诊次数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号